PEOPLE - Merck KGaA makes management changes:
This article was originally published in Clinica
Merck KGaA (Germany) has made some senior management changes. Dr Jan Sombroeck becomes a board member, succeeding Klaus Gruber, who is due to retire at the end of June. Dr Sombroeck becomes head of Merck's preclinical R&D Pharma. Dr Inge Lues is promoted to vice-president, heading preclinical R&D pharma. She is currently responsible for Merck's biomedical research.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.